Paxlovid (Nirmatrelvir/Ritonavir) (Paxlovid 150 mg/100 mg Film Kaplı Tablet) and Riociguat: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Inhibition of multiple CYP and P-gp/BCRP pathways can increase riociguat exposure and hypotension.
Clinical significance and safety
Paxlovid (Nirmatrelvir/Ritonavir) and Riociguat: A specialist should assess the combination before treatment starts. Adding such an inhibitor to stable riociguat is not recommended in the product information. Starting riociguat in the inhibitor’s presence requires a supervised initiation and titration plan with close blood-pressure monitoring. Do not start, stop or switch either medicine yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.